# BPC-157 TB-500: The Wolverine Two-Peptide Blend, Drawn to Scale > BPC-157 TB-500 is the Wolverine blend — two synthetic peptides bolted together. Here is what each component's research measured, why they are paired, and where the combination evidence stops. The Wolverine blend bolts two synthetic peptides together: BPC-157, the cytoprotective and pro-angiogenic component, and TB-500, the actin-sequestration component. Each has its own measured single-component record. The joint between them is drawn dashed, because no controlled combination study exists. ## The two components on one sheet BPC-157 TB-500 is not one molecule. It is a research-community pairing of two distinct synthetic peptides, sold and discussed under the name Wolverine. Read it as an assembly drawing: two dimensioned components on a single sheet, each with its own callout block, joined by a leader line that is honestly dashed. Component one is BPC-157 (Body Protection Compound 157), a 15-amino-acid pentadecapeptide, sequence `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val` (`GEPPPGKPADDAGLV`), molecular weight `~1419.5 Da`, derived from a protein found in human gastric juice. Its role in the assembly is the local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 and activates the VEGFR2-Akt-eNOS pathway [2]. Component two is TB-500, a synthetic N-acetylated heptapeptide, `Ac-LKKTETQ`, molecular weight `~889.0 Da`, corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4. Its role is the cytoskeletal signal: the `LKKTETQ` motif binds monomeric G-actin and regulates the actin dynamics that drive cell migration [3]. Worth flagging at the outset: most of the efficacy data filed under the name TB-500 was actually generated with full-length Thymosin Beta-4, a larger molecule than the heptapeptide in the vial — a gap this digest keeps visible rather than smoothing over [7]. This page sets the two components side by side, and the rest of the site follows that drawing. The [Wolverine blend research summary](/research) details the measured findings; the [BPC-157 and TB-500 angiogenesis research](/angiogenesis) routes the vascular thread that is this digest's main lens; the [BPC-157 TB-500 dosage in the literature](/dosage) keeps the research-context dose figures; and the [Wolverine legal status and 503A compounding](/legal-status) page keeps the FDA, 503A, and WADA record. For the short answers, see the [frequently asked questions about the blend](/faq). ## BPC-157 and TB-500: What the Wolverine Blend Pairs The pairing of BPC-157 and TB-500 is a complementary-mechanism rationale. BPC-157 supplies a local, vessel-facing signal; TB-500 supplies an intracellular, cytoskeleton-facing signal. The two are described as acting through non-overlapping pathways, which is the basis of the marketed synergy claim. The measured halves are real and separately characterized. BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures, and reversed tendocyte growth inhibition into stimulation in vitro [1]. Thymosin Beta-4 — TB-500's parent protein — promotes cell migration, reduces scar-forming myofibroblasts, and drives angiogenesis [4]. The joint is the part that is not measured. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides administered together. On the drawing, the two component edges are solid; the synergy leader between them is dashed. ### BPC-157 with TB-500: The Combination Rationale {#bpc-157-with-tb-500} BPC-157 with TB-500 is paired on the theory that a pro-angiogenic, cytoprotective component plus an actin-sequestration, pro-migration component would cover more of the repair cascade than either alone. BPC-157's VEGFR2-Akt-eNOS angiogenesis [2] and Thymosin Beta-4's migration and angiogenic activity [4] are the two legs. The combined effect remains a theoretical extrapolation: no controlled head-to-head or combination study has tested it [8]. ### BPC-157 TB-500 Stack (Wolverine) {#bpc-157-tb-500-stack} The BPC-157 TB-500 stack is the same pairing under the community term stack. Commercial Wolverine vials are often labeled with a combined per-vial mass — for example 10 mg BPC-157 with 10 mg TB-500 — but no standardized composition or ratio is clinically validated. The stack inherits each component's evidence and each component's gaps. ## What Is the Wolverine Peptide Blend? The wolverine peptide blend is a research-community name for the two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity and not an approved product, and no standardized composition or ratio is clinically validated. ### What is BPC-157 and TB-500? {#what-is-bpc-157-and-tb-500} BPC-157 is a synthetic 15-amino-acid pentadecapeptide (`Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (`Ac-LKKTETQ`) corresponding to residues 17-23 of Thymosin Beta-4 [3]. The Wolverine blend pairs the two. Neither is an FDA-approved drug. ### What is the Wolverine peptide blend? {#what-is-the-wolverine-peptide-blend} A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and no standardized composition or ratio is clinically validated. The consolidated Thymosin Beta-4 literature is one of its two evidence sources [4]. ### What is the difference between BPC-157 and TB-500? {#difference-bpc-157-tb-500} BPC-157 is a 15-amino-acid pentadecapeptide (`~1419.5 Da`) from a human gastric-juice protein, acting on VEGFR2-Akt-eNOS angiogenic pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (`Ac-LKKTETQ`, `~889 Da`) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3]. They differ in size, source, and mechanism. ### What is the blend used for in research? {#blend-used-for-in-research} In animal models the two constituents are studied separately for tissue repair: BPC-157 for tendon, ligament, and muscle healing [1]; TB-500 / Thymosin Beta-4 for cell migration, wound re-epithelialization, and angiogenesis [4]. The combination itself has no controlled study [8]. ### Why are BPC-157 and TB-500 combined? {#why-are-bpc-157-and-tb-500-combined} The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) [2] while TB-500 supplies an intracellular actin-sequestration signal driving cell migration [3]. The synergy is a theoretical extrapolation from two non-overlapping mechanisms, not a finding from a controlled combination study [8]. ## BPC 157 TB 500 (Unhyphenated) BPC 157 TB 500 is the unhyphenated surface form of the same two-component blend. The chemistry does not change with the punctuation: BPC-157 remains the `~1419.5 Da` pentadecapeptide and TB-500 remains the `~889.0 Da` `Ac-LKKTETQ` heptapeptide. Both are supplied as lyophilized powders for research use, and both are prohibited by the World Anti-Doping Agency. ### Wolverine Injection: Routes Studied in Research {#wolverine-injection} Wolverine injection refers to the predominant research-community routes for the blend — subcutaneous and intramuscular. These routes are not drawn from controlled human efficacy trials. The underlying rodent efficacy studies for both peptides predominantly used the intraperitoneal route [1]; human single-agent reference points for full-length Thymosin Beta-4 used the intravenous route. The injection routes the community uses sit ahead of the human combination evidence, which does not exist [9]. --- The Wolverine blend read off a drafting table — BPC-157 and TB-500 set down as two dimensioned components, their measured findings inked solid and their unproven joint left dashed, with the FDA and WADA record kept in the title block and nothing here prescribed or sold.